Notice of Public Hearing: Kentucky Opioid Abatement Advisory Commission Explores $42 Million Funding for Ibogaine Research
    Notice of Public Hearing: Kentucky Opioid Abatement Advisory Commission Explores $42 Million Funding for Ibogaine Research
    News

    Frankfort, Kentucky

    Notice of Public Hearing: Kentucky Opioid Abatement Advisory Commission Explores $42 Million Funding for Ibogaine Research

    10 July 2023

    Expert clinicians and researchers to provide testimony at public hearing on July 17, 2023

    MEDIA CONTACT:
    Brad Burge
    brad@integrationcommunications.com
    Bryan Hubbard, Chair and Executive Director of the Kentucky Opioid Abatement Advisory Commission (KYOAAC), along with members of the Commission, will hold a public hearing and general information session on Monday, July 17, 2023, detailing the scientific basis of the Commission’s proposal to allocate funds totalling up to $42 million over 6 years towards research into the treatment of Opioid Use Disorder with the naturally occurring substance, ibogaine.
    If approved, these allocated funds will be dispensed from the state’s share of the $842 million in settlements with opioid manufacturers and distributors for their role in exacerbating the deadly opioid crisis. KYOAAC is responsible for distributing half of the settlement funds, or $421 million. The funds are to be distributed for the delivery of interventional, therapeutic, and recovery services for individuals, families, and communities which have been ravaged by the state's opioid addiction epidemic.
    The Commission will be joined by a panel of expert researchers and clinicians who will provide insight into the existing scientific data and current research into ibogaine therapy as a treatment for addiction, as well as ibogaine’s associated risks and benefits, legal status, and comparisons with the success rates of other treatment methods currently available in the state based on up-to-date public health statistics.
    Credentialed media interested in watching the public hearing may attend in person at the address below, or watch the livestream on July 17.
    WHO:
    W. Bryan Hubbard, Chairman and Executive Director, KYOAAC
    Dr. Nolan R. Williams, Associate Professor at Stanford University, and Director of Stanford Brain Stimulation Lab
    Dr. Kenneth Alper, Associate Professor of Psychiatry and Neurology at New York University School of Medicine
    Dr. Deborah Mash, Professor of Neurology and Molecular and Cellular Pharmacology at the Leonard M. Miller School of Medicine, and Director of the Brain Endowment Bank at University of Miami, and founder and CEO of DemeRx
    Dr. Srinivas Rao, Chief Scientific Officer, atai Life Sciences
    Dr. Douglas Kramer, Senior VP, Pharmacovigilance and Regulatory Affairs, Athenex, Inc.
    Juliana Mulligan MSW, psychotherapist and ibogaine treatment specialist
    Jessica Blackburn, ibogaine patient
    WHAT:
    Public hearing, and general information session
    WHEN:
    Monday, July 17, 2023 from 9 AM - 3:30 PM EDT
    WHERE:
    Administrative Office of the Courts Building
    Room A125
    1001 Vandalay Dr.
    Frankfort, KY 40601
    Or watch the public livestream at https://www.youtube.com/watch?v=WuOpoyITuqA.
    ###
    Powered by